Amylyx Pharmaceuticals (AMLX) Gross Margin: 2021-2024
Historic Gross Margin for Amylyx Pharmaceuticals (AMLX) over the last 2 years, with Dec 2024 value amounting to 100.00%.
- Amylyx Pharmaceuticals' Gross Margin rose 739.00% to 100.00% in Q4 2024 from the same period last year, while for Dec 2024 it was 94.88%, marking a year-over-year increase of 78.00%. This contributed to the annual value of 94.79% for FY2024, which is 69.00% up from last year.
- Per Amylyx Pharmaceuticals' latest filing, its Gross Margin stood at 100.00% for Q4 2024, which was down 0.00% from 100.00% recorded in Q3 2024.
- Amylyx Pharmaceuticals' 5-year Gross Margin high stood at 100.00% for Q3 2021, and its period low was 68.56% during Q3 2022.
- In the last 3 years, Amylyx Pharmaceuticals' Gross Margin had a median value of 94.30% in 2023 and averaged 92.70%.
- In the last 5 years, Amylyx Pharmaceuticals' Gross Margin plummeted by 3,144bps in 2022 and then surged by 2,678bps in 2023.
- Amylyx Pharmaceuticals' Gross Margin (Quarterly) stood at 100.00% in 2021, then tumbled by 3,144bps to 89.38% in 2022, then surged by 323bps to 92.61% in 2023, then soared by 739bps to 100.00% in 2024.
- Its Gross Margin was 100.00% in Q4 2024, compared to 100.00% in Q3 2024 and 99.22% in Q2 2024.